XML 43 R27.htm IDEA: XBRL DOCUMENT v3.25.1
Organization and Basis of Presentation (Details Narrative) - USD ($)
12 Months Ended
Feb. 11, 2025
Jun. 02, 2023
Dec. 31, 2024
Dec. 31, 2023
Mar. 14, 2025
Aug. 23, 2024
Aug. 19, 2024
Dec. 31, 2022
Apr. 09, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Minimum net stockholders equity maintaining in nasdaq   $ 2,500,000              
Stock holders' equity     $ (827,219) $ (3,994,762)       $ (5,165,227)  
Net loss     3,585,965 5,087,029          
Net cash used in operations     3,164,536 4,293,265          
Cash     1,038,952 4,203,488         $ 40,000
Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Contractual obligation     526,000            
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Purchasers [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Gross proceeds $ 1,050,003                
Subsequent Event [Member] | Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Contractual obligation         $ 526,000        
Minimum [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Stock holders' equity           $ 2,500,000 $ 2,500,000    
Common Stock [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Reverse stock split   1-for-10              
Stock holders' equity     (225) (225)       $ (166)  
Net loss              
Common Stock [Member] | Minimum [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Bid price   $ 1.00